


1. A compound of Formula I:



or a pharmaceutically acceptable salt thereof; wherein:

X is CH or N;

Y is H, cyano, halo, C₁₋₃ alkyl, or C₁₋₃ haloalkyl;

Z is CR⁴ or N;

W is CH or N;

when W is CH, then L is O, S, C(R⁶)₂, C(=O), C(=O)N(R⁷), C(=O)O, C(=O)C(R⁶)₂, S(=O), S(=O)₂, S(=O)N(R⁷), S(=O)₂N(R⁷), or C(=NR^{7a})N(R⁷); or

when W is N, then L is C(R⁶)₂, C(=O), C(=O)O, C(=O)N(R⁷), C(=O)C(R⁶)₂, S(=O), S(=O)₂, S(=O)N(R⁷), S(=O)₂N(R⁷), or C(=NR^{7a})N(R⁷);

R¹, R², R³, and R⁴ are each independently H, hydroxy, halo, C₁₋₃ alkyl, or C₁₋₃ haloalkyl;

each R⁵ is independently hydroxy, C₁₋₄ alkoxy, fluorine, C₁₋₄ alkyl, hydroxy-C₁₋₄-alkyl, C₁₋₄ alkoxy-C₁₋₄-alkyl, or C₁₋₄ fluoroalkyl;

each R⁶ is, independently, H or C₁₋₄ alkyl; or

two R⁶ groups, together with the carbon atom to which they are attached, form a 3-, 4-, 5-, or 6-membered cycloalkyl ring;

R⁷ is H or C₁₋₄ alkyl;

R^{7a} is H, OH, CN, C₁₋₄ alkoxy, or C₁₋₄ alkyl;

or R⁷ and R^{7a}, taken together with the C(=N)N moiety to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl ring or a 5- or 6-membered heteroaryl ring;

A is H, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₀ heterocycloalkyl, C₆₋₁₀ aryl, or C₁₋₁₀ heteroaryl; wherein said C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₀ heterocycloalkyl, C₆₋₁₀ aryl, and C₁₋₁₀ heteroaryl are each optionally substituted with p independently selected R⁸ substituents; wherein p is 1, 2, 3, 4, or 5; provided when L is O, S, C(=O), C(=O)O, S(=O), or S(=O)₂, then A is not H;

each R⁸ is independently selected from halo, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ cycloalkyl-C₁₋₄-alkyl, C₂₋₁₀ heterocycloalkyl, C₂₋₁₀ heterocycloalkyl-C₁₋₄-alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl-C₁₋₄-alkyl, C₁₋₁₀ heteroaryl, C₁₋₁₀ heteroaryl-C₁₋₄-alkyl, -OR^a, -SR^a, -S(=O)R^b, -S(=O)₂R^b, -S(=O)₂NR^cR^f, -C(=O)R^b, -C(=O)OR^a, -C(=O)NR^cR^f, -OC(=O)R^b, -OC(=O)NR^cR^f, -NR^eR^f, -NR^cC(=O)R^d, -NR^cC(=O)OR^d, -NR^eC(=O)NR^d, -NR^cS(=O)₂R^d, and -NR^cS(=O)₂NR^eR^f; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ cycloalkyl-C₁₋₄-alkyl, C₂₋₁₀ heterocycloalkyl, C₂₋₁₀ heterocycloalkyl-C₁₋₄-alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl-C₁₋₄-alkyl, C₁₋₁₀ heteroaryl, and C₁₋₁₀ heteroaryl-C₁₋₄-alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^g groups;

each R^a, R^c, R^d, R^e, and R^f is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ cycloalkyl-C₁₋₄-alkyl, C₂₋₁₀ heterocycloalkyl, C₂₋₁₀ heterocycloalkyl-C₁₋₄-alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl-C₁₋₄-alkyl, C₁₋₁₀ heteroaryl, and C₁₋₁₀ heteroaryl-C₁₋₄-alkyl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ cycloalkyl-C₁₋₄-alkyl, C₂₋₁₀ heterocycloalkyl, C₂₋₁₀ heterocycloalkyl-C₁₋₄-alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl-C₁₋₄-alkyl, C₁₋₁₀ heteroaryl, and C₁₋₁₀ heteroaryl-C₁₋₄-alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^g groups;

each R^b is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ cycloalkyl-C₁₋₄-alkyl, C₂₋₁₀ heterocycloalkyl, C₂₋₁₀ heterocycloalkyl-C₁₋₄-alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl-C₁₋₄-alkyl, C₁₋₁₀ heteroaryl, and C₁₋₁₀ heteroaryl-C₁₋₄-alkyl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ cycloalkyl-C₁₋₄-alkyl, C₂₋₁₀ heterocycloalkyl, C₂₋₁₀ heterocycloalkyl-C₁₋₄-alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl-C₁₋₄-alkyl, C₁₋₁₀ heteroaryl, and C₁₋₁₀ heteroaryl-C₁₋₄-alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^g groups;

each R^g is independently selected from halo, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₃-alkyl, C₂₋₇ heterocycloalkyl, C₂₋₇ heterocycloalkyl-C₁₋₃-alkyl, phenyl, phenyl-C₁₋₃-alkyl, C₁₋₇ heteroaryl, C₁₋₇ heteroaryl-C₁₋₃-alkyl,

-OR^{a1}, -SR^{a1}, -S(=O)R^{b1}, -S(=O)₂R^{b1}, -S(=O)₂NR^{e1}R^{f1}, -C(=O)R^{b1}, -C(=O)OR^{a1}, -C(=O)NR^{e1}R^{f1}, -OC(=O)R^{b1}, -OC(=O)NR^{e1}R^{f1}, -NR^{e1}R^{f1}, -NR^{e1}C(=O)R^{d1}, -NR^{e1}C(=O)OR^{d1}, -NR^{e1}C(=O)NR^{d1}, -NR^{e1}S(=O)₂R^{d1}, and -NR^{e1}S(=O)₂NR^{e1}R^{f1}; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₃-alkyl, C₂₋₇ heterocycloalkyl, C₂₋₇ heterocycloalkyl-C₁₋₃-alkyl, phenyl, phenyl-C₁₋₃-alkyl, C₁₋₇ heteroaryl, and C₁₋₇ heteroaryl-C₁₋₃-alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^h groups;

each R^{a1}, R^{c1}, R^{d1}, R^{e1}, and R^{f1} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₃-alkyl, C₂₋₇ heterocycloalkyl, C₂₋₇ heterocycloalkyl-C₁₋₃-alkyl, phenyl, phenyl-C₁₋₃-alkyl, C₁₋₇ heteroaryl, and C₁₋₇ heteroaryl-C₁₋₃-alkyl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₃-alkyl, C₂₋₇ heterocycloalkyl, C₂₋₇ heterocycloalkyl-C₁₋₃-alkyl, phenyl, phenyl-C₁₋₃-alkyl, C₁₋₇ heteroaryl, and C₁₋₇ heteroaryl-C₁₋₃-alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^h groups;

each R^{b1} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₃-alkyl, C₂₋₇ heterocycloalkyl, C₂₋₇ heterocycloalkyl-C₁₋₃-alkyl, phenyl, phenyl-C₁₋₃-alkyl, C₁₋₇ heteroaryl, and C₁₋₇ heteroaryl-C₁₋₃-alkyl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₃-alkyl, C₂₋₇ heterocycloalkyl, C₂₋₇ heterocycloalkyl-C₁₋₃-alkyl, phenyl, phenyl-C₁₋₃-alkyl, C₁₋₇ heteroaryl, and C₁₋₇ heteroaryl-C₁₋₃-alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^h groups;

each R^h is independently selected from cyano, halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, amino, C₁₋₄ alkylamino, di-C₁₋₄-alkylamino, hydroxy-C₁₋₄ alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, cyano-C₁₋₄ alkyl, thio, C₁₋₆ alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, carbamyl, C₁₋₆ alkylcarbamyl, di(C₁₋₆ alkyl)carbamyl, carboxy, C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylcarbonylamino, C₁₋₆ alkylsulfonylamino, aminosulfonyl, C₁₋₆ alkylaminosulfonyl, di(C₁₋₆ alkyl)aminosulfonyl, aminosulfonylamino, C₁₋₆ alkylaminosulfonylamino, di(C₁₋₆ alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₆ alkylaminocarbonylamino, and di(C₁₋₆ alkyl)aminocarbonylamino;

m is 0, 1, or 2; and

n is 0, 1, 2, 3, or 4.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
- X is CH or N;
- Y is H, cyano, halo, C₁₋₃ alkyl, or C₁₋₃ haloalkyl;
- Z is CR⁴ or N;
- W is CH or N;
- when W is CH, then L is O, S, C(R⁶)₂, C(=O), C(=O)N(R⁷), C(=O)O, C(=O)C(R⁶)₂, S(=O), S(=O)₂, S(=O)N(R⁷), or S(=O)₂N(R⁷); or
- when W is N, then L is C(R⁶)₂, C(=O), C(=O)O, C(=O)N(R⁷), C(=O)C(R⁶)₂, S(=O), S(=O)₂, S(=O)N(R⁷), or S(=O)₂N(R⁷);
- R¹, R², R³, and R⁴ are each independently H, hydroxy, halo, C₁₋₃ alkyl, or C₁₋₃ haloalkyl;
- each R⁵ is independently hydroxy, C₁₋₄ alkoxy, fluorine, C₁₋₄ alkyl, hydroxy-C₁₋₄-alkyl, C₁₋₄ alkoxy-C₁₋₄-alkyl, or C₁₋₄ fluoroalkyl;
- each R⁶ is, independently, H or C₁₋₄ alkyl; or
- two R⁶ groups, together with the carbon atom to which they are attached, form a 3-, 4-, 5-, or 6-membered cycloalkyl ring;
- R⁷ is H or C₁₋₄ alkyl;
- A is C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₀ heterocycloalkyl, C₆₋₁₀ aryl, or C₁₋₁₀ heteroaryl;
- wherein said C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₀ heterocycloalkyl, C₆₋₁₀ aryl, and C₁₋₁₀ heteroaryl are each optionally substituted with p independently selected R⁸ substituents; wherein p is 1, 2, 3, 4, or 5;
- each R⁸ is independently selected from halo, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ cycloalkyl-C₁₋₄-alkyl, C₂₋₁₀ heterocycloalkyl, C₂₋₁₀ heterocycloalkyl-C₁₋₄-alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl-C₁₋₄-alkyl, C₁₋₁₀ heteroaryl, C₁₋₁₀ heteroaryl-C₁₋₄-alkyl, -OR^a, -SR^a, -S(=O)R^b, -S(=O)₂R^b, -S(=O)₂NR^cR^f, -C(=O)R^b, -C(=O)OR^a, -C(=O)NR^cR^f, -OC(=O)R^b, -OC(=O)NR^cR^f, -NR^cR^f, -NR^cC(=O)R^d, -NR^cC(=O)OR^d, -NR^eC(=O)NR^d, -NR^cS(=O)₂R^d, and -NR^cS(=O)₂NR^eR^f; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ cycloalkyl-C₁₋₄-alkyl, C₂₋₁₀ heterocycloalkyl, C₂₋₁₀ heterocycloalkyl-C₁₋₄-alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl-C₁₋₄-alkyl, C₁₋₁₀ heteroaryl, and C₁₋₁₀ heteroaryl-C₁₋₄-alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^g groups;

each R^a , R^c , R^d , R^e , and R^f is independently selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} -alkyl, C_{2-10} heterocycloalkyl, C_{2-10} heterocycloalkyl- C_{1-4} -alkyl, C_{6-10} aryl, C_{6-10} aryl- C_{1-4} -alkyl, C_{1-10} heteroaryl, and C_{1-10} heteroaryl- C_{1-4} -alkyl; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} -alkyl, C_{2-10} heterocycloalkyl, C_{2-10} heterocycloalkyl- C_{1-4} -alkyl, C_{6-10} aryl, C_{6-10} aryl- C_{1-4} -alkyl, C_{1-10} heteroaryl, and C_{1-10} heteroaryl- C_{1-4} -alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^g groups;

each R^b is independently selected from C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} -alkyl, C_{2-10} heterocycloalkyl, C_{2-10} heterocycloalkyl- C_{1-4} -alkyl, C_{6-10} aryl, C_{6-10} aryl- C_{1-4} -alkyl, C_{1-10} heteroaryl, and C_{1-10} heteroaryl- C_{1-4} -alkyl; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} -alkyl, C_{2-10} heterocycloalkyl, C_{2-10} heterocycloalkyl- C_{1-4} -alkyl, C_{6-10} aryl, C_{6-10} aryl- C_{1-4} -alkyl, C_{1-10} heteroaryl, and C_{1-10} heteroaryl- C_{1-4} -alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^g groups;

each R^g is independently selected from halo, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl- C_{1-3} -alkyl, C_{2-7} heterocycloalkyl, C_{2-7} heterocycloalkyl- C_{1-3} -alkyl, phenyl, phenyl- C_{1-3} -alkyl, C_{1-7} heteroaryl, C_{1-7} heteroaryl- C_{1-3} -alkyl, $-OR^{a1}$, $-SR^{a1}$, $-S(=O)R^{b1}$, $-S(=O)_2R^{b1}$, $-S(=O)NR^{c1}R^{f1}$, $-C(=O)R^{b1}$, $-C(=O)OR^{a1}$, $-C(=O)NR^{c1}R^{f1}$, $-OC(=O)R^{b1}$, $-OC(=O)NR^{c1}R^{f1}$, $-NR^{c1}R^{f1}$, $-NR^{c1}C(=O)R^{d1}$, $-NR^{c1}C(=O)OR^{d1}$, $-NR^{c1}C(=O)NR^{d1}$, $-NR^{c1}S(=O)_2R^{d1}$, and $-NR^{c1}S(=O)_2NR^{e1}R^{f1}$; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl- C_{1-3} -alkyl, C_{2-7} heterocycloalkyl, C_{2-7} heterocycloalkyl- C_{1-3} -alkyl, phenyl, phenyl- C_{1-3} -alkyl, C_{1-7} heteroaryl, and C_{1-7} heteroaryl- C_{1-3} -alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^h groups;

each R^{a1} , R^{c1} , R^{d1} , R^{e1} , and R^{f1} is independently selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl- C_{1-3} -alkyl, C_{2-7} heterocycloalkyl, C_{2-7} heterocycloalkyl- C_{1-3} -alkyl, phenyl, phenyl- C_{1-3} -alkyl, C_{1-7} heteroaryl, and C_{1-7} heteroaryl- C_{1-3} -alkyl; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl- C_{1-3} -alkyl, C_{2-7} heterocycloalkyl, C_{2-7} heterocycloalkyl- C_{1-3} -alkyl, phenyl, phenyl- C_{1-3} -alkyl, C_{1-7} heteroaryl, and C_{1-7} heteroaryl- C_{1-3} -alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^h groups;

each R^{bi} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₃-alkyl, C₂₋₇ heterocycloalkyl, C₂₋₇ heterocycloalkyl-C₁₋₃-alkyl, phenyl, phenyl-C₁₋₃-alkyl, C₁₋₇ heteroaryl, and C₁₋₇ heteroaryl-C₁₋₃-alkyl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₃-alkyl, C₂₋₇ heterocycloalkyl, C₂₋₇ heterocycloalkyl-C₁₋₃-alkyl, phenyl, phenyl-C₁₋₃-alkyl, C₁₋₇ heteroaryl, and C₁₋₇ heteroaryl-C₁₋₃-alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^h groups;

each R^h is independently selected from cyano, halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, amino, C₁₋₄ alkylamino, di-C₁₋₄-alkylamino, thio, C₁₋₆ alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, carbamyl, C₁₋₆ alkylcarbamyl, di(C₁₋₆ alkyl)carbamyl, carboxy, C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxy carbonyl, C₁₋₆ alkylcarbonylamino, C₁₋₆ alkylsulfonylamino, aminosulfonyl, C₁₋₆ alkylaminosulfonyl, di(C₁₋₆ alkyl)aminosulfonyl, aminosulfonylamino, C₁₋₆ alkylaminosulfonylamino, di(C₁₋₆ alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₆ alkylaminocarbonylamino, and di(C₁₋₆ alkyl)aminocarbonylamino;

m is 0, 1, or 2; and

n is 0, 1, 2, 3, or 4.

3. The compound of either claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein X is N.
4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein Z is N.
5. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein Z is CH.
6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein W is N.

7. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein L is $C(R^6)_2$, $C(=O)$, $C(=O)O$, $C(=O)N(R^7)$, $S(=O)_2$, $S(=O)_2N(R^7)$ or $C(=NR^{7a})N(R^7)$.
8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R^6 is H, R^7 is H or methyl, and R^{7a} is CN.
9. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein W is CH.
10. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein L is O.
11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein Y is cyano.
12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , and R^4 are each H.
13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein n is 0.
14. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein m is 1.
15. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein A is H, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, 1,2-dimethylpropyl, 1-(tert-butyl)methyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, a tetrahydropyran ring, a pyrrolidine ring, a piperidine ring, a pyridine ring, a pyrimidine ring, a thiazole ring, or a pyrazine ring; each of which is optionally substituted with p independently selected R^8 substituents; provided when L is O, S, $C(=O)$, $C(=O)O$, $S(=O)$, or $S(=O)_2$, then A is not H.

16. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein each R^g is independently selected from halo, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, $-OR^a$, $-SR^a$, $-S(=O)R^b$, $-S(=O)_2R^b$, $-S(=O)_2NR^cR^f$, $-C(=O)R^b$, $-C(=O)OR^a$, $-C(=O)NR^cR^f$, $-OC(=O)R^b$, $-OC(=O)NR^cR^f$, $-NR^cR^f$, $-NR^cC(=O)R^d$, $-NR^cC(=O)OR^d$, $-NR^cC(=O)NR^d$, $-NR^cS(=O)_2R^d$, and $-NR^cS(=O)_2NR^cR^f$; wherein said C_{1-6} alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^g groups.

17. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein each R^g is independently selected from halo, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, C_{2-7} heterocycloalkyl, $-OR^a$, $-C(=O)OR^a$, or $-NR^cR^f$; wherein said C_{1-6} alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^g groups; and wherein each R^a , R^c , and R^f is independently selected from H, C_{1-6} alkyl, and C_{1-6} haloalkyl.

18. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein each R^g is independently selected from halo, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, C_{2-7} heterocycloalkyl, $-OR^{a1}$, $-S(=O)_2R^{b1}$, $-S(=O)_2NR^{c1}R^{f1}$, $-C(=O)R^{b1}$, $-C(=O)OR^{a1}$, and $-NR^{c1}R^{f1}$; wherein said C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{2-7} heterocycloalkyl and are each optionally substituted by 1, 2, 3, or 4 independently selected R^h groups.

19. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein each R^g is independently selected from C_{2-7} heterocycloalkyl, $-OR^{a1}$, $-NR^{c1}R^{f1}$; wherein said C_{2-7} heterocycloalkyl is optionally substituted by 1 or 2 R^h groups independently selected from fluoro, OH, C_{1-3} alkyl, C_{1-3} alkoxy, and hydroxy- C_{1-4} alkyl; and wherein each R^{a1} , R^{c1} and R^{f1} are independently selected from H, C_{3-7} cycloalkyl, and C_{1-6} alkyl.

20. The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein each R^h is independently selected from fluoro, OH, C_{1-3} alkyl, C_{1-3} alkoxy, and hydroxy- C_{1-4} alkyl.

21. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

X is N;

Z is N;

R¹, R², and R³ are each H;

Y is cyano;

W is N and L is C(R⁶)₂, C(=O), C(=O)N(R⁷), S(=O)₂, or S(=O)₂N(R⁷); or

W is CH and L is O;

A is C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₀ heterocycloalkyl, C₆₋₁₀ aryl, or C₁₋₁₀ heteroaryl;

wherein said C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₀ heterocycloalkyl, C₆₋₁₀ aryl, and C₁₋₁₀ heteroaryl are each optionally substituted with p independently selected R⁸ substituents; wherein p is 1, 2, 3, 4, or 5;

each R⁸ is independently selected from halo, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -OR^a, -SR^a, -S(=O)R^b, -S(=O)₂R^b, -S(=O)₂NR^cR^f, -C(=O)R^b, -C(=O)OR^a, -C(=O)NR^cR^f, -OC(=O)R^b, -OC(=O)NR^cR^f, -NR^cR^f, -NR^cC(=O)R^d, -NR^cC(=O)OR^d, -NR^eC(=O)NR^d, -NR^cS(=O)₂R^d, and -NR^cS(=O)₂NR^eR^f; wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^g groups;

each R^g is independently selected from halo, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, C₂₋₇ heterocycloalkyl, -OR^{al}, -S(=O)₂R^{bl}, -S(=O)₂NR^{cl}R^{fl}, -C(=O)R^{bl}, -C(=O)OR^{al}, and -NR^{cl}R^{fl}; wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₂₋₇ heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^h groups;

each R^a, R^c, R^d, R^e, and R^f is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R^b is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

each R^{al}, R^{cl}, R^{dl}, R^{el}, and R^{fl} is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R^{bl} is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

n is 0; and

m is 1.

22. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

X is N;

Z is N;

R¹, R², and R³ are each H;

Y is cyano;

W is N and L is C(R⁶)₂, C(=O), C(=O)N(R⁷), S(=O)₂, or S(=O)₂N(R⁷); or

W is CH and L is O;

A is C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₀ heterocycloalkyl, C₆₋₁₀ aryl, or C₁₋₁₀ heteroaryl;

wherein said C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₀ heterocycloalkyl, C₆₋₁₀ aryl, and C₁₋₁₀ heteroaryl are each optionally substituted with p independently selected R⁸ substituents; wherein p is 1, 2, 3, 4, or 5;

each R⁸ is independently selected from halo, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -OR^a, or -NR^eR^f; wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^g groups;

each R^g is independently selected from C₂₋₇ heterocycloalkyl and -NR^{e1}R^{f1}; wherein said C₂₋₇ heterocycloalkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^h groups;

each R^h is independently selected from C₁₋₄ alkyl;

each R^a, R^e, and R^f is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R^{a1}, R^{e1}, and R^{f1} is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

n is 0; and

m is 1.

23. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

X is N;

Z is N;

R¹, R², and R³ are each H;

Y is cyano;

W is N and L is C(R⁶)₂, C(=O), C(=O)N(R⁷), S(=O)₂, or S(=O)₂N(R⁷);

R⁶ is H;

R⁷ is H or methyl;

A is methyl, ethyl, cyclopropyl, phenyl, a pyrrolidine ring, a piperidine ring, a pyridine ring, a pyrimidine ring, a thiazole ring, or a pyrazine ring; each of which is optionally substituted with p independently selected R⁸ substituents; wherein p is 1, 2, or 3;

each R⁸ is independently selected from halo, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -OR^a, or -NR^eR^f; wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^g groups;

each R^g is independently selected from C₂₋₇ heterocycloalkyl and -NR^{e1}R^{f1}; wherein said C₂₋₇ heterocycloalkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^h groups;

each R^h is independently C₁₋₄ alkyl;

each R^a, R^e, and R^f is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R^{a1}, R^{e1}, and R^{f1} is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

n is 0; and

m is 1.

24. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

X is N;

Z is N;

R¹, R², and R³ are each H;

Y is cyano;

W is CH and L is O;

R⁶ is H;

R⁷ is H or methyl;

A is phenyl, which is optionally substituted with p independently selected R⁸ substituents; wherein p is 1, 2, or 3;

each R⁸ is independently selected from halo, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -OR^a, or -NR^eR^f; wherein said C₁₋₆ alkyl is optionally substituted by p independently selected R^g groups;

each R^g is independently selected from C₂₋₇ heterocycloalkyl and -NR^{e1}R^{f1}; wherein said C₂₋₇ heterocycloalkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^h groups;

each R^h is independently C₁₋₄ alkyl;

each R^a, R^e, and R^f is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R^{a1} , R^{e1} , and R^{f1} is independently selected from H, C_{1-6} alkyl, and C_{1-6} haloalkyl;
n is 0; and
m is 1.

25. The compound ~~accordingly~~ of to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

X is N;

Z is N;

R^1 , R^2 , and R^3 are each H;

Y is cyano;

W is N and L is $C(R^6)_2$, $C(=O)$, $C(=O)O$, $C(=O)N(R^7)$, $S(=O)_2$, $S(=O)_2N(R^7)$ or $C(=NR^{7a})N(R^7)$; or

W is CH and L is O;

R^6 is H;

R^7 is H or methyl;

R^{7a} is CN;

A is H, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, 1,2-dimethylpropyl, 1-(tert-butyl)methyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, a tetrahydropyran ring, a pyrrolidine ring, a piperidine ring, a pyridine ring, a pyrimidine ring, a thiazole ring, or a pyrazine ring; wherein said methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, 1,2-dimethylpropyl, 1-(tert-butyl)methyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, a tetrahydropyran ring, pyrrolidine ring, piperidine ring, pyridine ring, pyrimidine ring, thiazole ring, and pyrazine ring are each optionally substituted with p independently selected R^8 substituents; provided when L is O, S, $C(=O)$, $C(=O)O$, $S(=O)$, or $S(=O)_2$, then A is not H;

each R^8 is independently selected from halo, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, C_{2-7} heterocycloalkyl, $-OR^a$, $-C(=O)OR^a$, or $-NR^eR^f$; wherein said C_{1-6} alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^g groups; and wherein each R^a , R^e , and R^f is independently selected from H, C_{1-6} alkyl, and C_{1-6} haloalkyl;

each R^g is independently selected from C_{2-7} heterocycloalkyl, $-OR^{a1}$, $-NR^{e1}R^{f1}$; wherein said C_{2-7} heterocycloalkyl is optionally substituted by 1 or 2 R^h groups independently selected

from fluoro, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, and hydroxy-C₁₋₄ alkyl; and wherein each R^{a1}, R^{e1} and R^{f1} are independently selected from H, C₃₋₇ cycloalkyl, and C₁₋₆ alkyl;

p is 1, 2, or 3;

m is 1; and

n is 0.

26. The compound ~~accordingly to~~ claim 1, or a pharmaceutically acceptable salt thereof, wherein:

X is N;

Z is N;

R¹, R², and R³ are each H;

Y is cyano;

W is N and L is C(R⁶)₂, C(=O), C(=O)O, C(=O)N(R⁷), S(=O)₂, or S(=O)₂N(R⁷); or

W is CH and L is O;

R⁶ is H;

R⁷ is H or methyl;

A is methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, 1,2-dimethylpropyl, 1-(tert-butyl)methyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, a tetrahydropyran ring, a pyrrolidine ring, a piperidine ring, a pyridine ring, a pyrimidine ring, a thiazole ring, or a pyrazine ring; each of which is optionally substituted with p independently selected R⁸ substituents;

each R⁸ is independently selected from halo, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, C₂₋₇ heterocycloalkyl, -OR^a, -C(=O)OR^a, or -NR^eR^f; wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^g groups; and wherein each R^a, R^e, and R^f is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;


each R^g is independently selected from C₂₋₇ heterocycloalkyl, -OR^{a1}, -NR^{e1}R^{f1}; wherein said C₂₋₇ heterocycloalkyl is optionally substituted by 1 or 2 R^h groups independently selected from fluoro, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, and hydroxy-C₁₋₄ alkyl; and wherein each R^{a1}, R^{e1} and R^{f1} are independently selected from H, C₃₋₇ cycloalkyl, and C₁₋₆ alkyl;

p is 1, 2, or 3;

m is 1; and

n is 0.


27. The compound ~~according to~~ any one of claims 1-2, 21-23, and 25-26, wherein said compound has Formula IV:



IV

or a pharmaceutically acceptable salt thereof.

28. The compound ~~according to~~ any one of claims 1-2, 21-22, and 24-26, wherein said compound has Formula V:



V

or a pharmaceutically acceptable salt thereof.

29. The compound according to claim 1, selected from:

3-[(4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}piperazin-1-yl)methyl]-5-fluorobenzonitrile;

3-[(4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}piperazin-1-yl)methyl]-6-(dimethylamino)-2-fluorobenzonitrile;

4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[4-fluoro-2-(trifluoromethyl)phenyl]piperazine-1-carboxamide;

{3-(4-{[(2S)-2-methylpyrrolidin-1-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-(4-{[(2S)-2-ethylpyrrolidin-1-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-{4-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

[1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-(4-{2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)cyclobutyl]acetonitrile;

{3-[4-(3,5-difluorobenzoyl)piperazin-1-yl]-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-{4-[(2-chloro-5-fluoropyridin-3-yl)carbonyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-{4-[(5-fluoropyridin-3-yl)carbonyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-{4-[2-(difluoromethyl)-3-fluoroisonicotinoyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

3-[(4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}piperazin-1-yl)carbonyl]-5-fluorobenzonitrile;

[1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-(4-{4-(trifluoromethyl)-1,3-thiazol-2-yl]carbonyl}piperazin-1-yl)cyclobutyl]acetonitrile;

[1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-(4-{6-(trifluoromethyl)pyrazin-2-yl]carbonyl}piperazin-1-yl)cyclobutyl]acetonitrile;

{3-[4-(3,4-difluorobenzoyl)piperazin-1-yl]-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-

pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-[4-(2-chloro-3,6-difluorobenzyl)piperazin-1-yl]-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-{4-[3-fluoro-5-(trifluoromethyl)benzoyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-{4-[2-fluoro-4-(trifluoromethyl)benzoyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-[4-(pyrrolidin-1-ylcarbonyl)piperazin-1-yl]-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-(4-{[6-(trifluoromethyl)pyridin-2-yl]carbonyl}piperazin-1-yl)cyclobutyl} acetonitrile;

{3-(4-{[6-(difluoromethyl)pyridin-2-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-{4-[2-fluoro-3-(trifluoromethyl)benzoyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-{4-[(5-fluoropyridin-3-yl)methyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-{4-[(2-isopropylpyrimidin-4-yl)carbonyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-[4-(piperidin-1-ylcarbonyl)piperazin-1-yl]-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-{4-[4-fluoro-3-(trifluoromethoxy)benzoyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-(4-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-{4-[4-chlorobenzoyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{3-{4-[2-fluoro-4-(trifluoromethyl)benzoyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-

yl]cyclobutyl}-N,N-dimethylpiperazine-1-carboxamide;

{3-(4-{3-[(dimethylamino)methyl]-5-fluorobenzoyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

{3-(4-{3-[(dimethylamino)methyl]-5-fluorobenzyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

{3-[4-(ethylsulfonyl)piperazin-1-yl]-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

{3-[4-(cyclopropylsulfonyl)piperazin-1-yl]-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N,N-dimethylpiperazine-1-sulfonamide;

4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-ethyl-N-methylpiperazine-1-carboxamide;

{3-{4-[3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzoyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

{3-[4-(3-fluoro-5-[(2S)-2-methylpyrrolidin-1-yl]methyl}phenoxy)piperidin-1-yl]-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

{3-(4-{3-[(dimethylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

[1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-(4-{2-(trifluoromethyl)pyrimidin-4-yl}carbonyl)piperazin-1-yl]cyclobutyl}acetonitrile-d1; and
or a pharmaceutically acceptable salt of any of the aforementioned.

30. The compound of claim 1, selected from:

3-[4-{cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}piperazin-1-yl)carbonyl]-5-[(dimethylamino)methyl]benzonitrile;

3-[4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}piperazin-1-yl)methyl]-5-[(dimethylamino)methyl]benzonitrile;

3-[4-{cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}piperazin-1-yl)methyl]-5-[(dimethylamino)methyl]benzonitrile;

{trans-3-{4-[3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{cis-3-{4-[3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzyl]piperazin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-[(ethylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl} piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

6-[(4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} piperazin-1-yl)carbonyl]-2-(trifluoromethyl)pyrimidine-4-carboxylic acid;

{trans-3-(4-{[6-(azetidin-1-ylmethyl)-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl} piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-[(methylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl} piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-(hydroxymethyl)-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl} piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-[(dimethylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl} piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-(pyrrolidin-1-ylmethyl)-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl} piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-(aminomethyl)-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl} piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-[(isopropylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl} piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-[(cyclobutylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl} piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-[(tert-butylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-(1-hydroxy-1-methylethyl)-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{cis-3-(4-{[6-(1-hydroxy-1-methylethyl)-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-(methoxymethyl)-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-(1-aminocyclobutyl)-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{cis-3-(4-{[6-(1-aminocyclobutyl)-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-[1-(dimethylamino)cyclobutyl]-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{cis-3-(4-{[6-[1-(dimethylamino)cyclobutyl]-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-[(dimethylamino)methyl]-6-(trifluoromethyl)pyridin-2-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile ;

{trans-3-(4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-[(methylamino)methyl]-6-(trifluoromethyl)pyridin-2-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-(1-methoxy-1-methylethyl)-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-[1-(methylamino)cyclobutyl]-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

2-[(4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}piperazin-1-yl)carbonyl]-6-(trifluoromethyl)isonicotinonitrile;

{trans-3-(4-{[6-(1-hydroxycyclobutyl)-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-(4,5-dihydro-1H-imidazol-2-yl)-6-(trifluoromethyl)pyridin-2-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{3-(difluoromethyl)-5-[(dimethylamino)methyl]benzoyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-(1-hydroxy-1-methylethyl)-6-(trifluoromethyl)pyridin-2-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-(methoxymethyl)-6-(trifluoromethyl)pyridin-2-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-(1-hydroxy-1-methylethyl)-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)-1-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-isopropyl-N-methylpiperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-

yl]cyclobutyl}-N-methyl-N-propylpiperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-ethylpiperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[3-(dimethylamino)propyl]-N-methylpiperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-cyclopropyl-N-methylpiperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-methyl-N-(2,2,2-trifluoroethyl)piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-isopropylpiperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-(trans-4-hydroxycyclohexyl)piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(3R)-tetrahydrofuran-3-yl]piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-(2-hydroxycyclopentyl)piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(1S,2R)-2-hydroxycyclopentyl]piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-cyclopentylpiperazine-1-carboxamide;

{trans-3-(4-{[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl}piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-(cyclopropylmethyl)piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(1R)-1,2-dimethylpropyl]piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(1S)-1,2-dimethylpropyl]piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-

yl]cyclobutyl}piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(1S)-1-cyclopropylethyl]piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(1R)-1-cyclopropylethyl]piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-cyclopropylpiperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-cyclobutylpiperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-(2,2-dimethylpropyl)piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-isobutylpiperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(1R)-1-methylpropyl]piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(1S)-1-methylpropyl]piperazine-1-carboxamide;

4-{cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-cyclobutylpiperazine-1-carboxamide;

4-{cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(1R)-1-methylpropyl]piperazine-1-carboxamide;

4-{cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(1S)-1-methylpropyl]piperazine-1-carboxamide;

4-{cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-cyclopropylpiperazine-1-carboxamide;

4-{cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-isopropylpiperazine-1-carboxamide;

4-{cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-cyclopentylpiperazine-1-carboxamide;

4-{cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-

yl]cyclobutyl}-N-[(1R)-1,2-dimethylpropyl]piperazine-1-carboxamide;

4-{cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(1S)-1,2-dimethylpropyl]piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-methylpiperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(1R)-2,2,2-trifluoro-1-methylethyl]piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl]piperazine-1-carboxamide;

4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[(1S)-1-(trifluoromethyl)propyl]piperazine-1-carboxamide;

[trans-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-(4-{[(2R)-2-(trifluoromethyl)pyrrolidin-1-yl]carbonyl}piperazin-1-yl)cyclobutyl]acetonitrile;

[trans-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-(4-{[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]carbonyl}piperazin-1-yl)cyclobutyl]acetonitrile;

N'-cyano-4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N,N-dimethylpiperazine-1-carboximidamide;

{trans-3-[4-(methylsulfonyl)piperazin-1-yl]-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile ;

isopropyl 4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}piperazine-1-carboxylate;

{cis-3-(4-{[4-(methoxymethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-(methoxymethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{cis-3-(4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-(1-hydroxy-1-methylethyl)-6-(trifluoromethyl)pyridin-2-

yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-[(tert-butylamino)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{cis-3-(4-{[4-[(tert-butylamino)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-[(dimethylamino)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-[(ethylamino)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-[(methylamino)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

2-[(1-{cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}piperidin-4-yl)oxy]-6-(trifluoromethyl)isonicotinonitrile;

2-[(1-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}piperidin-4-yl)oxy]-6-(trifluoromethyl)isonicotinonitrile;

{cis-3-(4-[3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzoyl]piperazin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

3-[(4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}piperazin-1-yl)carbonyl]-5-[(dimethylamino)methyl]benzonitrile;

{cis-3-(4-{[6-(pyrrolidin-1-ylmethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{cis-3-(4-{[6-(morpholin-4-ylmethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{cis-3-(4-{[6-(azetidin-1-ylmethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

3-[(1-{cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}piperidin-4-yl)oxy]-5-[(dimethylamino)methyl]benzonitrile;

{cis-3-{4-[3-[(dimethylamino)methyl]-5-(trifluoromethyl)phenoxy]piperidin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;
 {cis-3-{4-[3-[(diethylamino)methyl]-5-(trifluoromethyl)phenoxy]piperidin-1-yl}-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;
 {cis-3-(4-{3-(difluoromethyl)-5-[(dimethylamino)methyl]phenoxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;
 {cis-3-[4-({6-chloro-4-[(dimethylamino)methyl]pyridin-2-yl}oxy)piperidin-1-yl]-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;
 {cis-3-(4-{[6-[(dimethylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;
 {cis-3-(4-{[6-[(ethylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;
 {cis-3-(4-{[6-[(3-hydroxyazetidin-1-yl)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;
 {cis-3-(4-{[6-methyl-2-(trifluoromethyl)pyrimidin-4-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;
 {cis-3-(4-{[6-(hydroxymethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;
 {cis-3-(4-{[6-(aminomethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;
 4-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}-N-[2,2,2-trifluoro-1-(trifluoromethyl)ethyl]piperazine-1-carboxamide;
 {trans-3-(4-{[4-{[(2-hydroxy-1,1-dimethylethyl)amino]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;
 {trans-3-(4-{[4-{[(2-hydroxyethyl)amino]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;
 {trans-3-(4-{[4-{[(3-hydroxypropyl)amino]methyl}-6-(trifluoromethyl)pyridin-2-

yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-(azetidin-1-ylmethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-[(3-hydroxyazetidin-1-yl)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-(pyrrolidin-1-ylmethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-(morpholin-4-ylmethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-[(3,3-difluoropyrrolidin-1-yl)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-{[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[4-(1-hydroxy-1-methylethyl)-6-(trifluoromethyl)pyridin-2-yl]carbonyl}piperazin-1-yl)-1-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{cis-3-(4-{[6-(2-hydroxyethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{trans-3-(4-{[6-(2-hydroxyethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

{cis-3-(4-{[4-[(2-oxo-1,3-oxazolidin-3-yl)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile; and

{trans-3-(4-{[4-[(2-oxo-1,3-oxazolidin-3-yl)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile;

or a pharmaceutically acceptable salt of any of the aforementioned.

31. The compound ~~according to~~ any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, wherein the cyclobutyl ring in Formula I is the *cis* form.

32. The compound ~~according to~~ any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, wherein the cyclobutyl ring in Formula I is the *trans* form.

33. The compound of claim 1, wherein the compound is *trans*-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-(4-{[2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)cyclobutyl]acetonitrile, or a pharmaceutically acceptable salt thereof.

34. The compound of claim 1, wherein the compound is {*trans*-3-(4-{[4-[(3-hydroxyazetidin-1-yl)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile, or a pharmaceutically acceptable salt thereof.

35. A composition comprising a compound ~~according to~~ any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

36. A composition comprising a compound of claim 33, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

37. A composition comprising a compound of claim 34, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

38. A Use of a compound according to any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for ~~method of modulating inhibiting~~

an activity of JAK1 comprising contacting JAK1 with a compound according to any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof.

~~3539.~~ ~~A method according to~~ The use of claim 3438, wherein said compound, or pharmaceutically acceptable salt thereof, is selective for JAK1 over JAK2.

~~3640.~~ Use of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for ~~A method of treating the treatment of an~~ autoimmune disease, a cancer, a myeloproliferative disorder, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof.

~~3741.~~ ~~A method~~ The use according to claim 3640, wherein said autoimmune disease is a skin disorder, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, type I diabetes, lupus, inflammatory bowel disease, Crohn's disease, myasthenia gravis, immunoglobulin nephropathies, myocarditis, or autoimmune thyroid disorder.

~~3842.~~ ~~A method~~ The use according to claim 3640, wherein said autoimmune disease is rheumatoid arthritis.

~~3943.~~ ~~A method~~ The use according to claim 3640, wherein said autoimmune disease is a skin disorder.

~~4044.~~ ~~A method~~ The use according to claim 3943, wherein said skin disorder is atopic dermatitis, psoriasis, skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization.

~~4145.~~ ~~A method~~ The use according to claim 3640, wherein said cancer is a solid tumor.

4246. ~~A method~~The use according to claim 3640, wherein said cancer is prostate cancer, renal cancer, hepatic cancer, breast cancer, lung cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease or pancreatic cancer.

4347. ~~A method~~The use according to claim 3640, wherein said cancer is lymphoma, leukemia, or multiple myeloma.

4448. ~~A method~~The use according to claim 3640, wherein said myeloproliferative disorder (MPD) is polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM), primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), idiopathic myelofibrosis (IMF), or systemic mast cell disease (SMCD).

4549. ~~A method~~The use according to claim 3640, wherein said myeloproliferative disorder is myelofibrosis.

4650. ~~A method~~The use according to claim 3640, wherein said myeloproliferative disorder is primary myelofibrosis (PMF).

4751. ~~A method~~The use according to claim 3640, wherein said bone resorption disease is osteoporosis, osteoarthritis, bone resorption associated with hormonal imbalance, bone resorption associated with hormonal therapy, bone resorption associated with autoimmune disease, or bone resorption associated with cancer.